# Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

> **NCT00653055** · PHASE1 · COMPLETED · sponsor: **Par Pharmaceutical, Inc.** · enrollment: 40 (actual)

## Conditions studied

- To Determine Bioequivalence Under Fasting Conditions

## Interventions

- **DRUG:** Cabergoline
- **DRUG:** Dostinex

## Key facts

- **NCT ID:** NCT00653055
- **Lead sponsor:** Par Pharmaceutical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2001-12
- **Final completion:** 2001-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2008-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00653055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00653055, "Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00653055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*